Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Amgen’s R&D chief Sean Harper retires to seek biotech post

Adds to trend in senior leaders

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Speech coincides with Biosimilars Action Plan

- PMLiVE

Daily Brief: Andrew Witty’s replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

The latest news from across pharma, biotech and healthcare

- PMLiVE

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

All the latest from the frontline of pharma, biotech and healthcare

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

Roche Basel Switzerland

Ocrevus helps Roche stave off biosimilar threat

Its low price strategy for the CD20-targeting antibody is paying off

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

- PMLiVE

Reig Jofre and LeanBio launch Syna Therapeutics

The new company will focus on the development of biosimilars

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links